secwatch.observer — SEC 8-K summary
======================================

Issuer:     COMPASS Pathways plc (CMPS)
CIK:        0001816590
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001628280-24-044400
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Pathways delays COMP360 phase 3 data to Q2 2025; workforce reduction of 30%
--------------------------------------------------------------------------------

- COMP005 phase 3 top-line data in TRD now expected Q2 2025; COMP006 data shifted to H2 2026 after unblinding risk.
- Workforce reduction of ~30% including senior management roles; non-COMP360 preclinical halted; digital health tools explored for externalization.
- Net loss Q3 2024 $38.5M ($0.56 loss per share) vs $33.4M loss ($0.67 loss per share) in Q3 2023.
- Cash and equivalents $207M as of Sept 30, 2024; projected to fund operations at least into 2026.
- R&D expenses rose to $32.9M in Q3 2024 from $21.5M in Q3 2023, driven by phase 3 clinical costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816590/000162828024044400/0001628280-24-044400-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816590/000162828024044400/cmps-20241031.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-044400

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer